(NNVC) is on My Radar Early This Morning—Take a Look at This One Right Now

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored See What Put (NNVC) on Krypton Street’s Radar This Morning — Monday, May 11, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get (NNVC) On Your Screen While It’s Still Early… May 11, 2026 (NNVC) is on My Radar Early This Morning—Take a Look at This One Right Now Dear Reader, The United States recorded 1,803 confirmed cases of a highly contagious rash-related illness through April 30, 2026 — and there is still no FDA-approved therapy for this condition anywhere in the world. On May 4, 2026, a small Connecticut nano-biopharmaceutical company changed that equation: the US FDA granted NanoViricides, Inc. (NYSE American: NNVC) — and its lead candidate NV-387 — Orphan Designation status for this illness, making it the first and only candidate in the world to hold that designation. With a Phase II pox-related trial now launching in the Democratic Republic of Congo, an active Rare Pediatric Disease Designation application that could unlock a transferable voucher worth $150M–$200M, and a market cap sitting under $35M, (NNVC) is one of the most interesting clinical-stage situations we have come across this year. And this is just some of the reasons why (NNVC) is topping our watchlist this morning—Monday, May 11, 2026. Here’s where (NNVC) gets even more exciting for us. Analyst Targets Suggest Over 300% to 400% Upside Potential From Recent Range… According to TipRanks, James Molloy, an analyst at Alliance Global Partners, has a $6 target on (NNVC) which suggests over 300% upside potential from its recent $1.37 range. In fact, since February, (NNVC) has made an approximate 85% move, from around $.85 on February 5, to $1.58 on May 6. And that’s not the only one covering (NNVC). David Bautz, PhD, from Zacks SCR, has a $7 valuation on (NNVC) which suggests over 400% upside potential. But the recent momentum and analyst coverage is only one part of the story. What makes (NNVC) stand out is the combination of a first-of-its-kind FDA designation, a platform designed for broad infectious-disease use, and multiple clinical paths already in motion. To understand why this tiny Connecticut company is drawing so much attention, it helps to start with what NanoViricides actually does. What NanoViricides Does (NNVC) is a Shelton, Connecticut–based clinical-stage nano-biopharmaceutical company founded in 2005 by President and CEO Dr. Anil R. Diwan. The company's central mission is to do for anti-vir-al medicine what penicillin did for bacterial infections — develop a class of broad-spectrum anti-vir-als capable of targeting a wide range of infectious agents. The company's proprietary "nanoviricide™" technology works by engineering nanomaterials that mimic the cellular receptors infectious agents use to enter human cells. When a pathogen binds to a nanoviricide instead of a healthy cell, it is rendered harmless. Because this mechanism uses the pathogen’s own biology against it, the company believes its anti-vir-als can function across many different strains — including those that mutate rapidly and evade traditional approaches. The platform is exclusively licensed from TheraCour Pharma, Inc., and (NNVC) holds worldwide exclusive perpetual licenses covering a broad range of serious infectious conditions — including HIV, Hepatitis B and C, Herpes Simplex, Rabies, Dengue, Ebola, West Nile, and select airborn illnesses. (NNVC)’s pipeline centers on two lead candidates. NV-387 is a broad-spectrum anti-vir-al in clinical development for respiratory infections, pox-related conditions, and the previously referenced rash-related illness. NV-HHV-1 is a topical cream in development for the treatment of shingles rash and herpes-related conditions. The Public Health Backdrop: A World With No Approved Therapy This highly contagious rash-related illness was once considered all but eliminated in the United States. That status has been reversed. From just 59 confirmed cases in 2023 and 285 in 2024, the US has already recorded 1,803 confirmed cases through April 30, 2026 — approaching the full-year 2025 total of 2,251, which included three deaths, in just four months. The surge is international: Bangladesh has recorded more than 35,000 cases in 2026 with over 227 child deaths, while Guatemala has an active outbreak with more than 5,300 cases and four fatalities. Immunization hesitancy has driven coverage rates below the 95% threshold needed to prevent community spread in many regions. Despite this resurgence, no approved therapy for this condition exists anywhere in the world. Without a therapeutic option, public health authorities are forced to quarantine all contacts of a confirmed case for at least 14 days — a socially and economically disruptive measure that results in significant school absences for children. An effective anti-vir-al therapy could reduce the need for mass quarantine and meaningfully lower disease severity, including life-threatening complications such as encephalitis and neurological disability. NV-387: A Single Candidate Addressing Multiple Unmet Needs (NNVC)’s lead anti-vir-al NV-387 is a broad-spectrum clinical-stage candidate. On May 4, 2026, the US FDA's Office of Orphan Products Development granted NV-387 ODD status for the previously referenced rash-related illness — the first such designation for any anti-vi-ral candidate targeting this condition in the world. This designation provides tax credits for qualified clinical trials, exemption from certain FDA user fees, and potential seven-year market exclusivity following approval. (NNVC) has also filed for a Rare Pediatric Disease Designation for NV-387 in this condition — a designation that, if granted and combined with the potential for FDA approval, would entitle the company to a Priority Review Voucher. A PRV significantly accelerates the FDA review timeline for an NDA and is transferable — historically fetching between $150M and $200M when sold. Given (NNVC)'s current market cap of approximately $22M, a successful PRV monetization would represent a significant early revenue event. On the pox-related front, (NNVC) announced April 1, 2026 that a Phase II clinical trial of NV-387 for a pox-type illness has commenced in the DRC following ACOREP regulatory approval. The trial follows NV-387's successful Phase I completion in healthy human volunteers with no reported adverse events and no dropouts — a critical safety milestone. There is currently no approved therapeutic for this pox-related condition anywhere in the world, and US Government strategic national stockpile contracts for existing pox-targeting anti-vir-als have reached several hundred mil-lions of dollars, setting a precedent for potential demand. (NNVC) estimates NV-387 addresses a total market potential of over $17B by 2030 across its multiple indications. 7 Reasons Why (NNVC) is Topping Our Watchlist This Morning—Monday, May 11, 2026… 1. Recent Momentum: (NNVC) has already shown recent momentum, moving approximately 85% from around $.85 in February to $1.58 in early May. 2. Analyst Coverage: (NNVC) has analyst targets of $6 and $7, which suggests over 300% to 400% upside potential from its recent $1.37 range. 3.Under-The-Radar: (NNVC) currently sits around a $35M market cap despite multiple clinical programs and regulatory milestones. 4. First-In-Class Status: (NNVC) holds the first-ever FDA ODD designation for this rash-related illness, setting it apart as the only candidate with that recognition globally. 5. Voucher Potential: (NNVC) has a pending designation that could unlock a transferable PRV historically valued between $150M and $200M. 6. Broad Platform: (NNVC) is built around a nanotechnology platform designed to target multiple infectious threats across several indications. 7. Active Trials: (NNVC) is advancing NV-387 through a Phase II study in the DRC following a clean Phase I safety outcome. Get (NNVC) On Your Screen While It’s Still Early… Taken together, these factors help explain why (NNVC) has just landed on our radar at a time when attention appears to be building. You have clearly defined analyst targets which suggest 300% to 400% upside potential from current levels, recent momentum, and a valuation that remains relatively small compared to the scope of its clinical programs and regulatory progress. Add in a first-of-its-kind FDA designation, the potential for a high-value transferable voucher, an active Phase II study following a clean safety readout, and a platform designed to address multiple infectious conditions—and you begin to see why this name is starting to stand out. With the opening bell just minutes away, this is a situation we are watching closely as the story continues to develop in real time. We’re watching (NNVC) closely this morning—Monday, May 11, 2026. Take a look before the day gets moving. Another update could be coming soon. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 05/11/2026 and ending on 05/11/2026 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid forty four thousand five hundred USD (“Funds”). These Funds were part of the seven thousand five hundred USD funds that TD Media LLC received from a third party named Interactive Offers LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/nnvc-fqsoe/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by alex@kryptonstreet.com

Tonight’s Preview: (Nasdaq: GTBP) Coverage is Dropping Early — Don't Sleep on This

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored GT Biopharma, Inc. (Nasdaq: GTBP) Headlines The Market Crux Watchlist Tomorrow Morning— Thursday, May 14, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. We’ll Be Opening (GTBP) Coverage Early Don’t Leave (GTBP) Off Tomorrow’s Watchlist… May 13, 2026 Tonight’s Preview | (Nasdaq: GTBP) Coverage is Dropping Early — Don't Sleep on This Dear Reader, Market Crux has identified a clinical-stage biotech below $0.50 that recently made an approximate 59% move in under a week while still flying well under the radar. GT Biopharma, Inc. (Nasdaq: GTBP) is developing a proprietary NK cell engager platform designed to activate the body’s natural killer cells directly in vivo, with clinical programs already underway and additional studies approaching. Backed by two active clinical-stage assets, a growing pipeline, and several defined clinical timelines extending through 2026, (GTBP) quickly became one of the primary names on the Market Crux watchlist ahead of Thursday morning, May 14, 2026. What makes this setup stand out is the combination of near-term clinical timelines, recent momentum, and a platform aimed at several difficult-to-treat disease areas. For a company still flying this far under the radar, (GTBP) gives readers plenty to pay attention to as Thursday’s session approaches. How GT Biopharma, Inc. (Nasdaq: GTBP) Targets Cancer Differently GT Biopharma, Inc. (Nasdaq: GTBP) is a San Francisco-based clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary TriKE® (Tri-Specific NK Cell Engager) platform. Unlike CAR-T therapies — which require cells to be harvested and modified outside the body — (GTBP)’s approach is designed to harness and enhance the cancer-killing ability of a patient's own NK cells directly in vivo, without removing or modifying those cells prior to treatment. The company holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using the TriKE® technology. The TriKE® platform is built around a tri-specific molecule with three functional domains: an anti-CD16 nanobody that binds and activates NK cells via antibody-dependent cellular cytotoxicity (ADCC), an IL-15 crosslinker that promotes NK cell expansion and persistence at the tumor site, and an anti-tumor associated antigen (TAA) binding domain that directs NK cells to specific cancer markers. This modular architecture allows (GTBP) to efficiently adapt the platform across different tumor targets — a key design advantage. (GTBP)’s active pipeline includes three named TriKE® candidates: GTB-3650, a second-generation camelid nanobody TriKE® currently in a Phase 1 dose escalation trial for relapsed or refractory (r/r) CD33-expressing hematologic malignancies including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); GTB-5550, a B7-H3-targeted TriKE® that received FDA IND clearance in February 2026 with a Phase 1 basket trial planned for mid-2026; and GTB-7550, a CD19-targeted candidate in preclinical development for lupus and other autoimmune disorders. The $136B Immunotherapy Backdrop Behind (GTBP) The broader cancer immunotherapy market was valued at approximately $136B in 2025 and is projected to reach roughly $367B by 2035, growing at a compound annual growth rate (CAGR) of approximately 10.4%. Within that broader landscape, the NK cell therapeutics segment is expanding even faster — valued at $3.2B in 2024 and forecast to reach $8.6B by 2033. (GTBP)’s GTB-5550 program targets a portion of the estimated $362B global solid tumor market, according to the company's January 2026 IND announcement. The upcoming Phase 1 basket trial covers up to seven potential metastatic cancer cohorts: castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. The TriKE® mechanism is also designed to avoid the most severe side effects associated with competing modalities. CAR-T therapies are widely associated with cytokine release syndrome (CRS) and neurological complications stemming from T-cell hyperactivation. GTBP's approach selectively activates NK cells rather than T cells, potentially offering a more tolerable safety profile — an important distinction in the immunotherapy landscape. Big pharmaceutical companies have taken notice: Sanofi and Gilead both completed significant NK cell engager deals valued at over $1B in milestone and upfront payments, according to GT Biopharma's March 2026 corporate presentation. Early Data Behind The Platform (GTBP)’s clinical foundation is not speculative — the company's first-generation TriKE®, GTB-3550, completed a Phase 1 study in AML and MDS patients and demonstrated reproducible NK cell proliferation, activation, and persistence across all patients and all dose levels, with minimal clinically significant toxicity. In select patients, GTB-3550 showed reductions in CD33+ bone marrow blast levels: 33.3% in one patient, 61.7% in another, 63.6% in a third, and 50% in a fourth — encouraging early signals for a first-in-class modality at lower dose levels. Building on those results, (GTBP)’s second-generation candidate GTB-3650 incorporates camelid nanobody technology for improved potency, enhanced binding affinity, commercial manufacturing capabilities through Cytovance, and full proprietary ownership by GT Biopharma. The Phase 1 dose escalation trial (NCT06594445) is actively enrolling, with Cohort 5 dosing (25 µg/kg/day) expected to begin in Q2 2026 and the next data update anticipated in Q3 2026 — covering longer-term follow-up for patients in Cohorts 1 through 3, plus initial observations from Cohorts 4 and 5. (GTBP)’s Runway Into Q4 2026 According to (GTBP)’s full year 2025 financial results, the company held cash and cash equivalents of approximately $7M as of December 31, 2025, and an unaudited proforma cash balance of approximately $9M as of January 31, 2026. Management anticipates this runway to fund operations through Q4 2026 — spanning both the continued enrollment of the GTB-3650 Phase 1 trial and the planned mid-2026 initiation of the GTB-5550 basket trial. Full year 2025 R&D expenses came in at approximately $3.5M, down from $5.8M in 2024, primarily reflecting reduced production and material costs as the company sharpened its development focus. Why We’ll Have All Eyes On (GTBP) Tomorrow Morning —Thursday, May 14, 2026 … 1. FDA-Cleared Path: With GTB-5550 cleared by FDA for a planned mid-2026 Phase 1 basket study, (GTBP) has another clinical program approaching. 2. Recent Momentum: After an approximate 59% move in under a week, (GTBP) is now at the top of our watchlist. 3. Flying Under the Radar: With a market cap below $12M, (GTBP) sits in a smaller valuation range than many clinical-stage biotech names, which could suggest a higher-potential for growth. 4. Active Trial: The Phase 1 dose escalation study for GTB-3650 is actively enrolling, giving (GTBP) a live clinical timeline. 5. Platform Design: The TriKE® platform allows (GTBP) to adapt its NK cell engager approach across different tumor targets. 6. Funded Runway: Management expects current funding to support (GTBP) operations through Q4 2026. 7. Q3 Update: A GTB-3650 data update is anticipated in Q3 2026, giving (GTBP) a defined upcoming milestone. Don’t Leave (GTBP) Off Tomorrow’s Watchlist… Between the recent momentum, active clinical enrollment, upcoming Q3 2026 data timeline, and a second FDA-cleared program preparing to enter the clinic, (GTBP) is beginning to draw attention at a time when several important developments appear to be lining up simultaneously. The company’s TriKE® platform also gives (GTBP) exposure across multiple disease areas, while current funding guidance through Q4 2026 provides visibility into the next stage of clinical execution. For a biotech still operating with a market cap below $12M, the setup is difficult to ignore. Heading into Thursday morning, (GTBP) is the only one we’ll be tracking. Spend a few minutes on (GTBP) tonight, so you’re ready for tomorrow. Our morning update may be in your inbox early—keep an eye out for it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 05/13/2026 and ending on 05/14/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the one hundred fifty thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US). Neither Headline Media LLC, TD Media LLC and their member own shares of (GTBP:US). Please see important disclosure information here: https://marketcrux.com/disclosure/gtbp-7EFK4/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe Update Profile | About our service provider Sent by gary@marketcrux.net

Thursday’s Focus: (Nasdaq: GTBP) Coverage Drops Early Tomorrow—Here’s Why

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored GT Biopharma, Inc. (Nasdaq: GTBP) Gets The Krypton Street Spotlight Tomorrow —Thursday, May 14, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. (GTBP) Coverage Will Be Starting Early Make Room For (GTBP) On Tomorrow’s Watchlist … May 13, 2026 Thursday’s Focus | (Nasdaq: GTBP) Coverage Drops Early Tomorrow—Here’s Why Dear Reader, Krypton Street is tracking a clinical-stage biotech below $0.50 that just made an approximate 59% move in under a week — and despite the recent momentum, the name is still flying well below the radar. GT Biopharma, Inc. (Nasdaq: GTBP) is developing a proprietary natural killer (NK) cell engager platform that has already demonstrated proof of concept in cancer patients, while also preparing to advance a second clinical program targeting multiple solid tumor types in mid-2026. Between two active clinical-stage assets, funding guidance extending into Q4 2026, and a pipeline spanning oncology and autoimmune disease, (GTBP) quickly moved toward the top of the Krypton Street watchlist heading into tomorrow’s session— Thursday morning, May 14, 2026. What makes this setup stand out is the combination of near-term clinical timelines, recent momentum, and a platform aimed at several difficult-to-treat disease areas. For a company still flying this far under the radar, (GTBP) gives readers plenty to pay attention to as Thursday’s session approaches. How GT Biopharma, Inc. (Nasdaq: GTBP) Targets Cancer Differently GT Biopharma, Inc. (Nasdaq: GTBP) is a San Francisco-based clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary TriKE® (Tri-Specific NK Cell Engager) platform. Unlike CAR-T therapies — which require cells to be harvested and modified outside the body — (GTBP)’s approach is designed to harness and enhance the cancer-killing ability of a patient's own NK cells directly in vivo, without removing or modifying those cells prior to treatment. The company holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using the TriKE® technology. The TriKE® platform is built around a tri-specific molecule with three functional domains: an anti-CD16 nanobody that binds and activates NK cells via antibody-dependent cellular cytotoxicity (ADCC), an IL-15 crosslinker that promotes NK cell expansion and persistence at the tumor site, and an anti-tumor associated antigen (TAA) binding domain that directs NK cells to specific cancer markers. This modular architecture allows (GTBP) to efficiently adapt the platform across different tumor targets — a key design advantage. (GTBP)’s active pipeline includes three named TriKE® candidates: GTB-3650, a second-generation camelid nanobody TriKE® currently in a Phase 1 dose escalation trial for relapsed or refractory (r/r) CD33-expressing hematologic malignancies including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); GTB-5550, a B7-H3-targeted TriKE® that received FDA IND clearance in February 2026 with a Phase 1 basket trial planned for mid-2026; and GTB-7550, a CD19-targeted candidate in preclinical development for lupus and other autoimmune disorders. The $136B Immunotherapy Backdrop Behind (GTBP) The broader cancer immunotherapy market was valued at approximately $136B in 2025 and is projected to reach roughly $367B by 2035, growing at a compound annual growth rate (CAGR) of approximately 10.4%. Within that broader landscape, the NK cell therapeutics segment is expanding even faster — valued at $3.2B in 2024 and forecast to reach $8.6B by 2033. (GTBP)’s GTB-5550 program targets a portion of the estimated $362B global solid tumor market, according to the company's January 2026 IND announcement. The upcoming Phase 1 basket trial covers up to seven potential metastatic cancer cohorts: castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. The TriKE® mechanism is also designed to avoid the most severe side effects associated with competing modalities. CAR-T therapies are widely associated with cytokine release syndrome (CRS) and neurological complications stemming from T-cell hyperactivation. GTBP's approach selectively activates NK cells rather than T cells, potentially offering a more tolerable safety profile — an important distinction in the immunotherapy landscape. Big pharmaceutical companies have taken notice: Sanofi and Gilead both completed significant NK cell engager deals valued at over $1B in milestone and upfront payments, according to GT Biopharma's March 2026 corporate presentation. Proof of Concept in the Clinic — and a Second-Generation Upgrade (GTBP)’s clinical foundation is not speculative — the company's first-generation TriKE®, GTB-3550, completed a Phase 1 study in AML and MDS patients and demonstrated reproducible NK cell proliferation, activation, and persistence across all patients and all dose levels, with minimal clinically significant toxicity. In select patients, GTB-3550 showed reductions in CD33+ bone marrow blast levels: 33.3% in one patient, 61.7% in another, 63.6% in a third, and 50% in a fourth — encouraging early signals for a first-in-class modality at lower dose levels. Building on those results, (GTBP)’s second-generation candidate GTB-3650 incorporates camelid nanobody technology for improved potency, enhanced binding affinity, commercial manufacturing capabilities through Cytovance, and full proprietary ownership by GT Biopharma. The Phase 1 dose escalation trial (NCT06594445) is actively enrolling, with Cohort 5 dosing (25 µg/kg/day) expected to begin in Q2 2026 and the next data update anticipated in Q3 2026 — covering longer-term follow-up for patients in Cohorts 1 through 3, plus initial observations from Cohorts 4 and 5. Financial Position: Funded Into Q4 2026 According to (GTBP)’s full year 2025 financial results, the company held cash and cash equivalents of approximately $7M as of December 31, 2025, and an unaudited proforma cash balance of approximately $9M as of January 31, 2026. Management anticipates this runway to fund operations through Q4 2026 — spanning both the continued enrollment of the GTB-3650 Phase 1 trial and the planned mid-2026 initiation of the GTB-5550 basket trial. Full year 2025 R&D expenses came in at approximately $3.5M, down from $5.8M in 2024, primarily reflecting reduced production and material costs as the company sharpened its development focus. 7 Reasons We’re Watching (GTBP) Tomorrow Morning —Thursday, May 14, 2026 … 1. Flying Under the Radar: With a market cap below $12M, (GTBP) sits in a smaller valuation range than many clinical-stage biotech names, which could suggest a higher-potential for growth. 2. Recent Momentum: After an approximate 59% move in under a week, (GTBP) is now at the top of our watchlist. 3. Active Trial: The Phase 1 dose escalation study for GTB-3650 is actively enrolling, giving (GTBP) a live clinical timeline. 4. Q3 Update: A GTB-3650 data update is anticipated in Q3 2026, giving (GTBP) a defined upcoming milestone. 5. Platform Design: The TriKE® platform allows (GTBP) to adapt its NK cell engager approach across different tumor targets. 6. Cash Runway: Management expects current funding to support (GTBP) operations through Q4 2026. 7. FDA-Cleared Path: With GTB-5550 cleared by FDA for a planned mid-2026 Phase 1 basket study, (GTBP) has another clinical program approaching. Make Room For (GTBP) On Tomorrow’s Watchlist … Between the recent momentum, active clinical enrollment, upcoming Q3 2026 data timeline, and a second FDA-cleared program preparing to enter the clinic, (GTBP) is beginning to draw attention at a time when several important developments appear to be lining up simultaneously. The company’s TriKE® platform also gives (GTBP) exposure across multiple disease areas, while current funding guidance through Q4 2026 provides visibility into the next stage of clinical execution. For a biotech still operating with a market cap below $12M, the setup is difficult to ignore. (GTBP) will be front and center for us tomorrow morning—Thursday, May 14, 2026. Take a few minutes to look it over tonight. Keep an eye out for our morning update — it may hit sooner than you think. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter   KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 05/13/2026 and ending on 05/14/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the one hundred fifty thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (GTBP:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/gtbp-7EFK4/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by alex@kryptonstreet.com